2-羟基-4-[(4-甲氧基苄基)氧基]苯甲酸甲酯 | 148965-89-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-4-[(4-甲氧基苄基)氧基]苯甲酸甲酯
• 英文名称: methyl 2-hydroxy-4-((4-methoxybenzyl)oxy)benzoate
• 英文别名: Benzoic acid, 2-hydroxy-4-[(4-methoxyphenyl)methoxy]-, methyl ester；methyl 2-hydroxy-4-[(4-methoxyphenyl)methoxy]benzoate
• CAS: 148965-89-3
• 化学式: C₁₆H₁₆O₅
• 分子量: 288.3
• InChiKey: IANXOBHKQWFRAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-羟基-4-[(4-甲氧基苄基)氧基]苯甲酸甲酯 在 氢氧化钾 、 caesium carbonate 、 N,N'-羰基二咪唑 作用下， 以 DMF (N,N-dimethyl-formamide) 、 乙醇 、 水 为溶剂， 反应 1.0h， 生成 (2S)-1-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-[5-[(4-methoxybenzyl)oxy]-2-(morpholin-4-ylcarbonyl)phenoxy]propan-2-ol
  参考文献：
  名称：

  [EN] NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES
  [FR] NOUVELLES SPIROPIPERIDINES OU SPIROPYRROLIDINES TRICYCLIQUES

  摘要：

  本发明提供了公式（I）的化合物，其中m、R1、n、R2、q、X、Y、Z、R3、R4、R5、R6、R7、R8、t和R9如说明书所述，以及它们的制备过程、含有它们的药物组合物及其在治疗中的用途。

  公开号：

  WO2004005295A1
• 作为产物：
  描述：

  4-甲氧基苯甲醛 在 吡啶 、 氯化亚砜 、 钾硼氢 、 四丁基溴化铵 、 potassium carbonate 、 potassium iodide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 8.0h， 生成 2-羟基-4-[(4-甲氧基苄基)氧基]苯甲酸甲酯
  参考文献：
  名称：

  Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity

  摘要：

  A series of phenoxybutanoic acid derivatives were synthesized and tested for their antagonistic activity on the contraction of the rat thoracic aortic ring induced by endothelin-1. Preliminary screening results showed that 6e and 6g with benzoheterocycles demonstrated significant antagonistic activities when compared to the reference compound BQ123. The results from additional assays for the binding affinity and selectivity for endothelin receptors showed that 6e was a selective ETA antagonist with a nanomolar IC50. Moreover, 6e was effective in relieving hypoxia-induced pulmonary arterial hypertension and right ventricular weight ratio. Therefore, 6e may have potential for further development as a therapeutic agent for the treatment of cardiovascular diseases. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.01.003

文献信息

• COMPOUNDS AND THEIR USES AS MIF INHIBITORS
  申请人：Nanjing Immunophage BioTech Co., Ltd.

  公开号：US20210403484A1

  公开（公告）日：2021-12-30

  The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.

  本发明提供了一种可以用作巨噬细胞迁移抑制因子（MIF）抑制剂的化合物I的公式；本发明化合物的制备方法；包括本发明化合物的药物组合物；以及通过给予本发明化合物来治疗由MIF介导的疾病的用途和方法。
• Chromatography-free, Mitsunobu-triggered heterocyclizations of salicylhydroxamic acids to 3-hydroxybenzisoxazoles
  作者：Daniel Van Eker、Jay Chauhan、William A. Murphy、Ivie L. Conlon、Steven Fletcher

  DOI：10.1016/j.tetlet.2016.10.045

  日期：2016.11

  The Mitsunobu reaction has become one of the most powerful tools to alkylate acidic pronucleophiles. A significant caveat of Mitsunobu chemistry, however, is that the reaction mixture is often plagued with purification problems owing to the phosphine oxide and hydrazine dicarboxylate by-products. In addition to the development of more readily separable Mitsunobu reagents, the product’s physicochemical

  Mitsunobu反应已成为烷基化酸性原核亲核试剂的最强大工具之一。然而，Mitsunobu化学的一个重要警告是，由于氧化膦和二羧酸肼副产物，反应混合物经常受到纯化问题的困扰。除了开发更易于分离的Mitsunobu试剂外，还可以利用产品的物理化学性质来促进纯化。在这方面，我们介绍了通过水延异羟肟酸的Mitsunobu触发的杂环化反应快速有效地制备3-羟基苯并恶唑类化合物的方法，该方法可通过酸碱处理分离出来。如所期望的，一系列官能团与化学相容。
• [EN] NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] NOUVEAUX SPIRODERIVES TRICYCLIQUES EN TANT QUE MODULATEURS DE L'ACTIVITE DE RECEPTEUR DE CHIMIOKINE
  申请人：ASTRAZENECA AB

  公开号：WO2005037814A1

  公开（公告）日：2005-04-28

  The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  这项发明提供了式（I）的化合物，其中m、R1、n、R2、q、X、Y、Z、R3、R4、R5、R6、R7、R8、t和R9的定义如规范中所述，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• Novel tricyclic spiropiperidines or spiropyrrolidines
  申请人：Hossain Nafizal

  公开号：US20050245741A1

  公开（公告）日：2005-11-03

  The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, X, Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , t and R 9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）的化合物，其中m、R1、n、R2、q、X、Y、Z、R3、R4、R5、R6、R7、R8、t和R9如规范中所定义，以及它们的制备方法、包含它们的制药组合物及其在治疗中的应用。
• Substituted phenyl compounds
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US06211234B1

  公开（公告）日：2001-04-03

  Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.

  描述了化学式(I)的化合物，其中R1是氢，-(较低的烷基)q(CO2R6或OH)，—CN，—C(R7)═NOR8，NO2，—O(较低的烷基)R9，—C≡C—R10，—CR11═C(R12)(R13)，—C(═O)CH2C(═O)CO2H，—CO(R14)，烷基硫醇，烷基亚砜，烷基磺酰，氨基甲酰，硫代氨基甲酰，取代的氨基甲酰，取代的硫代氨基甲酰，磺酰胺或可选取代的含氮环，其中m，n，o和p独立地为零或1，而R2，R3，R4和R5是各种基团;以及其生理上可接受的盐，N-氧化物和前药。这些化合物具有内皮素拮抗剂活性，可用作药物。